News
AKTX
1.201
+7.12%
0.080
Weekly Report: what happened at AKTX last week (0408-0412)?
Weekly Report · 3d ago
Weekly Report: what happened at AKTX last week (0401-0405)?
Weekly Report · 04/08 10:00
Akari Therapeutics Non-GAAP EPS of $0.00
Seeking Alpha · 04/01 10:59
AKARI THERAPEUTICS REPORTS FULL-YEAR 2023 FINANCIAL RESULTS AND RECENT HIGHLIGHTS
Reuters · 04/01 10:30
Weekly Report: what happened at AKTX last week (0325-0329)?
Weekly Report · 04/01 09:59
Weekly Report: what happened at AKTX last week (0318-0322)?
Weekly Report · 03/25 10:01
Weekly Report: what happened at AKTX last week (0311-0315)?
Weekly Report · 03/18 09:59
Weekly Report: what happened at AKTX last week (0304-0308)?
Weekly Report · 03/11 09:58
Akari Therapeutics rises on all stock deal with Peak Bio
Seeking Alpha · 03/05 15:08
Akari Therapeutics Announces Strategic Merger with Peak Bio
TipRanks · 03/05 13:43
Akari Therapeutics Signs Merger-of-Equals with Peak Bio
Akari Therapeutics and Peak Bio have agreed to an all-stock merger of equals. The biotechnology companies will continue to operate under the Akari banner. Shareholders of each company are set to receive about 50% equity in the new company. The deal is expected to close late in the second quarter.
Dow Jones · 03/05 13:23
*Akari Therapeutics, Peak: Exchange Expected to Result in Implied Equity Ownership in Combined Co of About 50% for Akari Hldrs and About 50% for Peak Stockholders >AKTX
Dow Jones · 03/05 13:05
*Peak Stockholders Will Receive a Number of Akari Ordinary Shrs for Each Shr of Peak Stk They Own >AKTX
Dow Jones · 03/05 13:05
*Akari Therapeutics, Peak Bio: Post-merger Bd of Directors Will Consist of 3 Directors Selected by Each Co and 1 Independent Director Jointly Selected >AKTX
Dow Jones · 03/05 13:04
*Akari Therapeutics, Peak Bio: Hoyoung Huh, M.D., Ph.D. Expected to Serve as Chairman of Combined Entity >AKTX
Dow Jones · 03/05 13:04
*Akari Therapeutics, Peak Bio Entity Will Have Expanded Pipeline That Contains Multiple Compelling Assets Spanning Early and Late Development Stages >AKTX
Dow Jones · 03/05 13:02
*Akari Therapeutics, Peak Bio Combined Entity Will Operate as Akari Therapeutics and Continue to Be Listed and Trade on Nasdaq Cap Market as AKTX >AKTX
Dow Jones · 03/05 13:02
*Akari Therapeutics, Peak Bio to Merge as Equals in All-Stk Transaction >AKTX PKBO
Dow Jones · 03/05 13:01
AKTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Akari Therapeutics, Plc Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Akari Therapeutics, Plc and Peak Bio Inc. Is fair to Akari shareholders. The investigation concerns whether Akari and its board violated the federal securities laws and breached their fiduciary duties to shareholders.
Barchart · 03/05 10:51
Weekly Report: what happened at AKTX last week (0226-0301)?
Weekly Report · 03/04 10:00
More
Webull provides a variety of real-time AKTX stock news. You can receive the latest news about Akari Therapeutics Plc through multiple platforms. This information may help you make smarter investment decisions.
About AKTX
Akari Therapeutics, Plc is a late-stage biotechnology company. The Company is developing advanced therapies for autoimmune and inflammatory diseases. Its lead asset, investigational nomacopan, is a bispecific recombinant inhibitor of complement C5 activation and leukotriene B4 (LTB4) activity. Its pipeline includes a Phase 3 clinical trial program investigating nomacopan for pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA). It is conducting a clinical trial of subcutaneous nomacopan for the treatment of HSCT-TMA in pediatrics. The United States Food and Drug Administration (FDA) has granted Rare Pediatric Disease, Orphan Drug, and Fast Track designations to nomacopan for the treatment of pediatric HSCT-TMA. It is also investigating long-acting PASylated-nomacopan (PAS-nomacopan) for treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (dry AMD) in preclinical studies.